Abstract 520
Background
To evaluate the prognostic value of the proposed 8th Edition of the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) staging system for nasopharyngeal carcinoma (NPC) patients without cervical lymph node metastasis in comparison with the AJCC/ UICC 7th edition.
Methods
This is a retrospective study of 382 newly diagnosed non-metastatic NPC patients without cervical Lymph node metastasis who were treated with intensity-modulated radiotherapy (IMRT). All received elective neck irradiation to levels II, III, VA. Univariate and multivariate analyses were applied to evaluate the prognostic values between adjacent stage categories of the AJCC/ UICC 7th edition and the proposed 8th edition, including overall survival (OS), local relapse-free survival (LRFS), regional relapse-free survival (RRFS), distant metastasis-free survival (DMFS), and disease–free survival (DFS). The Akaike information criterion (AIC) and Harrell’s concordance index (c-index) were applied to compare the two prognostic systems with different numbers of stages.
Results
The median follow-up time was 61.1 months, with a range from 1 months to 91 months. The 5-year OS, LRFS, RFFS, DMFS and DFS were 86.9%, 96.7%, 99.1%, 93.3% and 82.6%, respectively. For LRFS and DMFS, the proposed eighth editions had superior prognostic value to the AJCC/ UICC 7th edition (P = 0.032 vs. P = 0.086 and P = 0.013 vs. P = 0.112). The 5-year OS and DFS were found to be significant both by the seventh and the proposed 8th editions. The difference between T1 and T3, T1 and T4, T2 and T3 and T2 and T4 by the proposed eighth edition were found to be significant (P = 0.042, P = 0.041, P = 0.000, and P = 0.000), however, there was no significant difference between T1 and T3, T2 and T3 by the seventh edition (P = 0.204, and P = 0.215). In addition, the difference between T1, T2, T3 with T4 were found to be significant in DFS (P = 0.000, P = 0.000, P = 0.037) and there was no significant difference between T1 and T3 (P = 0.162) by the seventh edition and there was significantly different between T2 and T4 (P = 0.026) by the proposed 8th editions. Multivariate analysis demonstrated that age, T stage of the proposed 8th editions and chemotherapy were independent prognostic factors for OS, LRFS, DMFS and DFS. The AIC value was smaller for the 8th edition compared to the 7th edition staging system. The C-index value was larger for the 8th edition compared to the 7th edition staging system.
Conclusions
IMRT with elective neck irradiation provides excellent local-regional control for NPC patients without cervical lymph node metastasis. The proposed eighth editions had superior prognostic value to the AJCC/ UICC 7th edition for LRFS and DMFS and lead a better distinction between adjacent T stages of nasopharyngeal carcinoma patients for OS and DFS. Overall, the proposed 8th UICC T classification seems to be superior to the 7th UICC T classification for nasopharyngeal carcinoma patients without cervical lymph node metastasis.
Clinical trial identification
Legal entity responsible for the study
Fudan University Shanghai Cancer Center.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
5720 - Evaluation of stemness and proliferation of human breast cancer stem cells (ALDH+) supplemented with heat-activated TGF-beta1 in the secretomes of stem cells from human exfoliated deciduous teeth (SHED)
Presenter: Septelia Wanandi
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4844 - Estrogen-related receptor _ as a potential molecular target for endometrial cancer therapy
Presenter: TETSUYA KOKABU
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1200 - Good tolerability and limited target-specific tissue distribution of an anti-L1CAM antibody administered to cynomolgus monkey indicates favorable safety profile of L1CAM-targeting therapies
Presenter: Jacques Gaudreault
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2905 - Pharmacokinetic drug-drug interaction between mitotane and etoposide in the treatment of adrenocortical carcinoma
Presenter: Anne Jouinot
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2597 - Real-world dosing of regorafenib (REG) in metastatic colorectal cancer (mCRC): final results from the prospective, observational CORRELATE study
Presenter: Juan Manuel O'Connor
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2663 - Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in metastatic colorectal cancer (mCRC) patients according to previous treatment with regorafenib in the international phase 3b PRECONNECT study
Presenter: Julien Taieb
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1670 - Treatment pattern and outcomes of trifluridine/tipiracil therapy for metastatic colorectal cancer in the real-world data from the JFMC50 study
Presenter: Takeshi Kawakami
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1088 - Phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients (pts) over 70 with previously treated metastatic colorectal adenocarcinoma (mCRC) FFCD 1404 - REGOLD
Presenter: thomas Aparicio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2548 - Prospective Evaluation of Regorafenib Dose Escalation Strategy with Low Starting Dose in Patients with Colorectal Cancer
Presenter: Toshiki Masuishi
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3244 - Regorafenib for metastatic colorectal carcinoma: a registry-based analysis
Presenter: Katerina Kopeckova
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract